Visfatin与非酒精性脂肪肝

Visfatin and non-alcoholic fatty liver disease

Visfatin是一新发现主要由内脏脂肪组织分泌的脂肪细胞因子,通过与胰岛素受体上不同于胰岛素结合部位的位点结合,可发挥拟胰岛素作用,进而参与调节糖脂代谢及炎症反应。非酒精性脂肪性肝病作为常见肝病,因其发病核心事件为胰岛素抵抗而常伴有代谢紊乱、炎症、氧化应激的发生。故在发病机制和病理生理上,Visfatin密切关联于非酒精性脂肪性肝病,探究两者关系或能为非酒精性脂肪性肝病防治提供新靶点。

Visfatin, a novel adipokine is highly expressed in visceral adipose tissue. It imitates the effects of insulin by binding to the insulin receptor at a site different from insulin, which involved in the process of glucose and lipid metabolism and inflammation. Non-alcoholic fatty liver disease （NAFLD） , a common disease with insulin resistance as a central pathogenic factor, is significantly associated with metabolic disorders, inflammatory response and oxidative stress. So, Visfatin may have close connection with pathogenesis and pathophysiology of NAFLD. Exploring the relationship between Visfatin and NAFLD may offer a new target to prevent and treat NAFLD.